{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:24:53Z","timestamp":1794252293376,"version":"4.9.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/13696998.2021.1894158","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T11:42:50Z","timestamp":1614339770000},"page":"421-431","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-7261","authenticated-orcid":false,"given":"Claire L.","family":"Simons","sequence":"first","affiliation":[{"name":"Pharmerit \u2013 An OPEN Health Company, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-9394","authenticated-orcid":false,"given":"Daniel","family":"Malone","sequence":"additional","affiliation":[{"name":"L. S. Skaggs Research Institute, The University of Utah College of Pharmacy, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-2557","authenticated-orcid":false,"given":"Gregory A.","family":"Maglinte","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-4078","authenticated-orcid":false,"given":"Tim","family":"Inocencio","sequence":"additional","affiliation":[{"name":"Pharmerit \u2013 An OPEN Health Company, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-7995","authenticated-orcid":false,"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[{"name":"Wade Outcomes Research and Consulting, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-5510","authenticated-orcid":false,"given":"Craig","family":"Bennison","sequence":"additional","affiliation":[{"name":"Pharmerit \u2013 An OPEN Health Company, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086"},{"key":"CIT0002","unstructured":"National Cancer Institute. SEER Cancer Statistics review: Non-Hodgkin Lymphoma. [Internet]. 2020; [cited 2020 Oct 1]. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2016\/results_merged\/sect_19_nhl.pdf."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15025"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1272688"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt366"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.01.009"},{"key":"CIT0013","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. [Internet]. 2020; [cited 2020 Jul 22]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"CIT0016","unstructured":"FDA. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. FDA [Internet]. 2020; [cited 2020 Oct 9]; Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"CIT0018","unstructured":"ClinicalTrials.gov. A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed\/Refractory Mantle Cell Lymphoma (ZUMA-2) [Internet]. clinicaltrials.gov. 2020; [cited 2020 Jul 22]. Report No.: NCT02601313. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601313."},{"key":"CIT0019","unstructured":"CDC. United States Life Tables. National Vital Statistics Reports. 2008. Vol. 61. No. 3."},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"key":"CIT0021","unstructured":"ICER. CAR-T Therapies: Final Evidence Report [Internet]. ICER. 2018; [cited 2020 Aug 11]. Available from: https:\/\/icer-review.org\/material\/car-t-final-report\/."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9876.2009.00677.x"},{"key":"CIT0023","unstructured":"Rutherford M, Lambert P, Sweeting M, et\u00a0al. NICE DSU Technical Support Document 21. Flexible Methods for Survival Analysis. [Internet]. 2020; [cited 2020 Dec 14]. Available from: http:\/\/nicedsu.org.uk\/."},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136382"},{"key":"CIT0026","unstructured":"Centers for Medicare & Medicaid Services. 2020. ASP Drug Pricing Files [Internet]. 2020; [cited 2020 Aug 12]. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2020-asp-drug-pricing-files."},{"key":"CIT0027","unstructured":"RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2020 [cited 2020 Aug 12]. Available from: https:\/\/www.micromedexsolutions.com"},{"key":"CIT0028","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:Supplement.","DOI":"10.1056\/NEJMoa1914347"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001722"},{"key":"CIT0030","unstructured":"Kaiser Family Foundation. Hospital adjusted expenses per inpatient day [Internet]. 2018; [cited 2020 Aug 12]. Available from: https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day\/."},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012576"},{"key":"#cr-split#-CIT0032.1","unstructured":"Centers for Medicare & Medicaid Services. Hospice Services Payment System - Base payment rate for FY 2020 for days 1-60. [Internet]. 2019"},{"key":"#cr-split#-CIT0032.2","unstructured":"[cited 2020 Aug 12]. Available from: http:\/\/medpac.gov\/docs\/default-source\/payment-basics\/medpac_payment_basics_19_hospice_final_sec.pdf."},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"CIT0035","unstructured":"HCUPnet. Healthcare Cost and Utilization Project [Internet]. HCUPnet. 2020; [cited 2020 Aug 26]. Available from: https:\/\/hcupnet.ahrq.gov\/#setup."},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004090740"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.3310\/hta21070"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"CIT0040","unstructured":"NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies [Internet]. NICE; 2018; [cited 2020 Aug 12]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA559."},{"key":"CIT0041","unstructured":"ICER. 2020. Value Assessment Framework: Final Framework [Internet]. 2020; [cited 2020 Aug 12]. Available from: https:\/\/icer-review.org\/material\/2020-value-assessment-framework-final-framework\/."},{"key":"CIT0042","unstructured":"Hettle R, Corbett M, Hinde S, et\u00a0al. Review of cost-effectiveness evidence for chimeric antigen receptor T-cell therapy and other interventions for acute lymphocytic leukaemia [Internet]. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. NIHR Journals Library. 2017; [cited 2020 Aug 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK424721\/."},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"CIT0044","unstructured":"Liu R, Snider JT, Diakite I, et\u00a0al. Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucal (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US. EHA library; 06\/12\/20; 294211; EP1731 [Internet]. 2020; [cited 2020 Oct 7]. Available from: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/294211\/julia.thornton.snide.cost.effectiveness.of.axicabtagene.ciloleucel.28axi-cel29.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1766%2Aot_id%3D23248%2Afeatured%3D16775."},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2859"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1774"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1198\/jasa.2009.tm08033"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X18820535"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.1894158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:40:29Z","timestamp":1641386429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.1894158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/13696998.2021.1894158"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.1894158","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}